HBIO — Harvard Bioscience, Inc.
Is HBIO overbought or oversold? Here is the current MarketMoodz read.
Harvard Bioscience, Inc. (HBIO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $8.91. The rating moved from Overbought to Neutral on November 16, 2026.
- Public ratingNeutral (as of November 17, 2026)
- Last close$8.91
- Last changeMoved from Overbought to Neutral on November 16, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
AI analysis
Harvard Bioscience, Inc. operates in a defensive, recurring‑demand niche supplying instruments and services to research and biopharma customers. Revenue is sensitive to R&D budgets but benefits from consumables and service annuity; growth levers include product launches, channel expansion via specialty distributors and targeted M&A. Near‑term outlook is mixed: stable demand expectations are offset by small‑cap volatility, competitive pressures and execution risk. Monitor order book trends, margin trajectory, cash flow and any strategic deals for clearer directional signals.
Key factors
- Niche position supplying life‑science research instruments and consumables with recurring consumable and service revenue potential
- Exposure to academic, pharma and biotech R&D budgets which can support steady demand but remain cyclical
- Opportunity from distributor shift to specialty care, infusion and biopharma services that can increase channel volume for specialized instruments
- Potential for growth via small strategic acquisitions or new product introductions given a history of tuck‑ins in the space
- Limited direct benefit from large‑cap pharma defensive flows but potential readthroughs from broader healthcare spending trends
- Smaller cap size gives flexibility but limits scale advantages versus large lab-equipment incumbents
Risks
- Small‑cap liquidity and higher share price volatility versus larger healthcare names
- Customer concentration and reliance on R&D spending; weakness in academic or pharma budgets could reduce orders
- Competitive pressure from larger instrument makers and lower‑cost vendors
- Supply chain disruptions or component shortages that can delay shipments and strain margins
- Execution risk on integration of acquisitions or new product launches
- Limited public disclosure in the provided window (no EDGAR updates here) increases short‑term information risk
See today's live rating, score and targets
Members see the live hourly rating for HBIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.